Abstract
Transcription requires the fine interplay between enhancers and transcription factors. Enhancers are able to activate transcription of genes involved in normal cell biology, whereas aberrant enhancer activity leads to oncogenesis. MYC is a well-established proto-oncogene involved in half of human cancers amplifying the output of its targets. The crosstalk between MYC and enhancers is known for many years since the discovery of IgH enhancer juxtaposition with MYC in high-grade lymphomas. Here, we focus mainly in the enhancers surrounding MYC in the 8q24 locus. That region comprises several enhancers that associate with other transcription factors, transmembrane receptors, and fusion genes composing complex regulatory networks aberrantly expressed in almost all types of hematological malignancies. Understanding the nature of these interactions in normal blood cells and in leukemias/lymphomas will expand MYC targeting options in the armamentarium against hematological cancers.
Similar content being viewed by others
References
Heinz S, Romanoski CE, Benner C, Allison KA, Kaikkonen MU, Orozco LD, Glass CK (2013) Effect of natural genetic variation on enhancer selection and function. Nature. 503:487–492
Huang J, Li K, Cai W, Liu X, Zhang Y, Orkin SH, Xu J, Yuan GC (2018) Dissecting super-enhancer hierarchy based on chromatin interactions. Nat Commun 9:943
Kim TK, Shiekhattar R (2015) Architectural and functional commonalities between enhancers and promoters. Cell 162:948–959
Long HK, Prescott SL, Wysocka J (2016) Ever-changing landscapes: transcriptional enhancers in development and evolution. Cell. 167:1170–1187
Fukaya T, Lim B, Levine M (2016) Enhancer control of transcriptional bursting. Cell. 166:358–368
Hanssen LLP, Kassouf MT, Oudelaar AM, Biggs D, Preece C, Downes DJ, Gosden M, Sharpe JA, Sloane-Stanley JA, Hughes JR, Davies B, Higgs DR (2017) Tissue-specific CTCF-cohesin-mediated chromatin architecture delimits enhancer interactions and function in vivo. Nat Cell Biol 19:952–961
Furlong EEM, Levine M (2018) Developmental enhancers and chromosome topology. Science. 361:1341–1345
Chen H, Levo M, Barinov L, Fujioka M, Jaynes JB, Gregor T (2018) Dynamic interplay between enhancer-promoter topology and gene activity. Nat Genet 50:1296–1303
Lim B, Heist T, Levine M, Fukaya T (2018) Visualization of transvection in living Drosophila embryos. Mol Cell 70:287–296.e6
Fulco CP, Munschauer M, Anyoha R, Munson G, Grossman SR, Perez EM, Kane M, Cleary B, Lander ES, Engreitz JM (2016) Systematic map** of functional enhancer-promoter connections with CRISPR interference. Science. 354:769–773
Mumbach MR, Satpathy AT, Boyle EA, Dai C, Gowen BG, Cho SW et al (2017) Enhancer connectome in primary human cells identifies target genes of disease-associated DNA elements. Nat Genet 49:1602–1612
Cinghu S, Yang P, Kosak JP, Conway AE, Kumar D, Oldfield AJ, Adelman K, Jothi R (2017) Intragenic enhancers attenuate host gene expression. Mol Cell 68:104–117.e6
Moorthy SD, Davidson S, Shchuka VM, Singh G, Malek-Gilani N, Langroudi L, Martchenko A, So V, Macpherson NN, Mitchell JA (2017) Enhancers and super-enhancers have an equivalent regulatory role in embryonic stem cells through regulation of single or multiple genes. Genome Res 27:246–258
Osterwalder M, Barozzi I, Tissières V et al (2018) Enhancer redundancy provides phenotypic robustness in mammalian development. Nature. 2018(554):239–243
Allahyar A, Vermeulen C, Bouwman BAM, Krijger PHL, Verstegen MJAM, Geeven G, van Kranenburg M, Pieterse M, Straver R, Haarhuis JHI, Jalink K, Teunissen H, Renkens IJ, Kloosterman WP, Rowland BD, de Wit E, de Ridder J, de Laat W (2018) Enhancer hubs and loop collisions identified from single-allele topologies. Nat Genet 50:1151–1160
Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA (2013) Super-enhancers in the control of cell identity and disease. Cell. 155:934–947
Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 153:320–334
Cao F, Fang Y, Tan HK et al (2017) Super-enhancers and broad H3K4me3 domains form complex gene regulatory circuits involving chromatin interactions. Sci Rep 7:2186
Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB, Lee TI, Young RA (2013) Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 153:307–319
Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, Bradner JE, Young RA (2015) Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell 58:362–370
Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, Wysocka J (2011) A unique chromatin signature uncovers early developmental enhancers in humans. Nature. 470:279–283
Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, Hanna J, Lodato MA, Frampton GM, Sharp PA, Boyer LA, Young RA, Jaenisch R (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 107:21931–21936
Henriques T, Scruggs BS, Inouye MO, Muse GW, Williams LH, Burkholder AB, Lavender CA, Fargo DC, Adelman K (2018) Widespread transcriptional pausing and elongation control at enhancers. Genes Dev 32:26–41
Sur I, Taipale J (2016) The role of enhancers in cancer. Nat Rev Cancer 16:483–493
Sun Y, Zhou B, Mao F et al (2018) HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell 34:643–658.e5
Org T, Duan D, Ferrari R, Montel-Hagen A, van Handel B, Kerényi MA, Sasidharan R, Rubbi L, Fujiwara Y, Pellegrini M, Orkin SH, Kurdistani SK, Mikkola HK (2015) Scl binds to primed enhancers in mesoderm to regulate hematopoietic and cardiac fate divergence. EMBO J 34:759–777
Xu J, Shao Z, Glass K, Bauer DE, Pinello L, Van Handel B, Hou S, Stamatoyannopoulos JA, Mikkola HK, Yuan GC, Orkin SH (2012) Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis. Dev Cell 23:796–811
Huang J, Liu X, Li D, Shao Z, Cao H, Zhang Y, Trompouki E, Bowman TV, Zon LI, Yuan GC, Orkin SH, Xu J (2016) Dynamic control of enhancer repertoires drives lineage and stage-specific transcription during hematopoiesis. Dev Cell 36:9–23
Romano O, Peano C, Tagliazucchi GM et al (2016) Transcriptional, epigenetic and retroviral signatures identify regulatory regions involved in hematopoietic lineage commitment. Sci Rep 6:24724
Lara-Astiaso D, Weiner A, Lorenzo-Vivas E, Zaretsky I, Jaitin DA, David E, Keren-Shaul H, Mildner A, Winter D, Jung S, Friedman N, Amit I (2014) Immunogenetics. Chromatin state dynamics during blood formation. Science 345:943–949
Javierre BM, Burren OS, Wilder SP et al (2016) Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters. Cell 167:1369–1384.e19
Luyten A, Zang C, Liu XS, Shivdasani RA (2014) Active enhancers are delineated de novo during hematopoiesis, with limited lineage fidelity among specified primary blood cells. Genes Dev 28:1827–1839
Katsumura KR, Ong IM, DeVilbiss AW, Sanalkumar R, Bresnick EH (2016) GATA factor-dependent positive-feedback circuit in acute myeloid leukemia cells. Cell Rep 16:2428–2441
Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, Yamamoto M (2014) A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25:415–427
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden V, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R (2014) A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 157:369–381
Benetatos L, Vartholomatos G (2018) Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes. Cell Mol Life Sci 75:1999–2009
Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, Goldmann J, Lajoie BR, Fan ZP, Sigova AA, Reddy J, Borges-Rivera D, Lee TI, Jaenisch R, Porteus MH, Dekker J, Young RA (2016) Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science. 351:1454–1458
Bretones G, Delgado MD, León J (2015) Myc and cell cycle control. Biochim Biophys Acta 1849:506–516
Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 151:56–67
Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, Zhao K, Levens D (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 151:68–79
Sabo A, Kress TR, Pelizzola M et al (2014) Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 511:488–492
Walz S, Lorenzin F, Morton J et al (2014) Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 511:483–487
Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV (2015) MYC, metabolism, and cancer. Cancer Discov 5(10):1024–1039
Benetatos L, Vartholomatos G, Hatzimichael E (2014) Polycomb group proteins and MYC: the cancer connection. Cell Mol Life Sci 71:257–269
Chen L, Alexe G, Dharia NV et al (2018) CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest 128:446–462
Ortega M, Bhatnagar H, Lin AP, Wang L, Aster JC, Sill H, Aguiar RC. (2015) A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies. Leukemia. 2015; 29(4):968–976
Dang CV (2012) MYC on the path to cancer. Cell. 149:22–35
Li Y, Choi PS, Casey SC, Dill DL, Felsher DW (2014) MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 26:262–272
Razavi P, Chang MT, Xu G et al (2018) The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34:427–438.e6
Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C, Cancer Genome Atlas Network (2018) Pan-cancer alterations of the MYC oncogene and its proximal network across the Cancer Genome Atlas. Cell Syst 6(3):282–300.e2
Yoshida GJ (2018) Emerging roles of Myc in stem cell biology and novel tumor therapies. J Exp Clin Cancer Res 37:173
Tenen DG (2003) Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89–101
Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH (2010) A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 143:313–324
Greaves M (2016) Leukaemia ‘firsts’ in cancer research and treatment. Nat Rev Cancer 16:163–172
Wolpaw AJ, Dang CV (2018) MYC-induced metabolic stress and tumorigenesis. Biochim Biophys Acta Rev Cancer 1870:43–50
Dejure FR, Eilers M (2017) MYC and tumor metabolism: chicken and egg. EMBO J 36:3409–3420
Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, Pasche AC, Knabenhans C, Macdonald HR, Trumpp A (2004) c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 18:2747–2763
Matsushita H, Nakajima H, Nakamura Y, Tsukamoto H, Tanaka Y, ** G, Yabe M, Asai S, Ono R, Nosaka T, Sugita K, Morimoto A, Hayashi Y, Hotta T, Ando K, Miyachi H (2008) C/EBPalpha and C/EBPvarepsilon induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene. Oncogene. 27:6749–6760
Ohanian M, Rozovski U, Kanagal-Shamanna R et al (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 9:1–12
Weng S, Matsuura S, Mowery CT, Stoner SA, Lam K, Ran D, Davis AG, Lo MC, Zhang DE (2017) Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity. Leukemia. 31:159–169
Guo Y, Niu C, Breslin P, Tang M, Zhang S, Wei W, Kini AR, Paner GP, Alkan S, Morris SW, Diaz M, Stiff PJ, Zhang J (2009) c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Blood. 114:2097–2106
Whitfield JR, Beaulieu ME, Soucek L (2017) Strategies to inhibit Myc and their clinical applicability. Front Cell Dev Biol 5:10
Cole MD (2014) MYC association with cancer risk and a new model of MYC-mediated repression. Cold Spring Harb Perspect Med 4:a014316
Kieffer-Kwon KR, Tang Z, Mathe E, Qian J, Sung MH, Li G, Resch W, Baek S, Pruett N, Grøntved L, Vian L, Nelson S, Zare H, Hakim O, Reyon D, Yamane A, Nakahashi H, Kovalchuk AL, Zou J, Joung JK, Sartorelli V, Wei CL, Ruan X, Hager GL, Ruan Y, Casellas R (2013) Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell. 155:1507–1520
Göndör A, Ohlsson R. (2018) Enhancer functions in three dimensions: beyond the flat world perspective. F1000Res. pii: F1000 Faculty Rev-681
Dixon JR, Xu J, Dileep V, Zhan Y, Song F, le VT, Yardımcı GG, Chakraborty A, Bann DV, Wang Y, Clark R, Zhang L, Yang H, Liu T, Iyyanki S, An L, Pool C, Sasaki T, Rivera-Mulia JC, Ozadam H, Lajoie BR, Kaul R, Buckley M, Lee K, Diegel M, Pezic D, Ernst C, Hadjur S, Odom DT, Stamatoyannopoulos JA, Broach JR, Hardison RC, Ay F, Noble WS, Dekker J, Gilbert DM, Yue F (2018) Integrative detection and analysis of structural variation in cancer genomes. Nat Genet 50:1388–1398
Cho SW, Xu J, Sun R, Mumbach MR et al (2018) Promoter of lncRNA gene PVT1 is a tumor-suppressor DNA boundary element. Cell 173:1398–1412.e22
McEwan MV, Eccles MR, Horsfield JA (2012) Cohesin is required for activation of MYC by estradiol. PLoS One 7:e49160
Zeid R, Lawlor MA, Poon E, e al. (2018) Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat Genet 50:515–523
Mahe M, Dufour F, Neyret-Kahn H et al (2018) An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med:10
Poli V, Fagnocchi L, Fasciani A et al (2018) MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun 9:1024
Pomerantz MM, Ahmadiyeh N, Jia L et al (2009) The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009(41):882–884
Yan J, Enge M, Whitington T, Dave K, Liu J, Sur I, Schmierer B, Jolma A, Kivioja T, Taipale M, Taipale J (2013) Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell. 154:801–813
Cohen AJ, Saiakhova A, Corradin O et al (2017) Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat Commun 8:14400
Lancho O, Herranz D (2018) The MYC enhancer-ome: long-range transcriptional regulation of MYC in cancer. Trends Cancer 4:810–822
Bahr C, von Paleske L, Uslu VV, Remeseiro S, Takayama N, Ng SW, Murison A, Langenfeld K, Petretich M, Scognamiglio R, Zeisberger P, Benk AS, Amit I, Zandstra PW, Lupien M, Dick JE, Trumpp A, Spitz F (2018) A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. Nature. 553:515–520
Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, Chaudhury S, Gilkes A, Knapper S, Beldjord K, Begum S, Rose S, Geddes N, Griffiths M, Standen G, Sternberg A, Cavenagh J, Hunter H, Bowen D, Killick S, Robinson L, Price A, Macintyre E, Virgo P, Burnett A, Craddock C, Enver T, Jacobsen SE, Porcher C, Vyas P (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19:138–152
Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L, Sundaravadanam Y, Luben R, Hayat S, Wang TT, Zhao Z, Cirlan I, Pugh TJ, Soave D, Ng K, Latimer C, Hardy C, Raine K, Jones D, Hoult D, Britten A, McPherson J, Johansson M, Mbabaali F, Eagles J, Miller JK, Pasternack D, Timms L, Krzyzanowski P, Awadalla P, Costa R, Segal E, Bratman SV, Beer P, Behjati S, Martincorena I, Wang JCY, Bowles KM, Quirós JR, Karakatsani A, la Vecchia C, Trichopoulou A, Salamanca-Fernández E, Huerta JM, Barricarte A, Travis RC, Tumino R, Masala G, Boeing H, Panico S, Kaaks R, Krämer A, Sieri S, Riboli E, Vineis P, Foll M, McKay J, Polidoro S, Sala N, Khaw KT, Vermeulen R, Campbell PJ, Papaemmanuil E, Minden MD, Tanay A, Balicer RD, Wareham NJ, Gerstung M, Dick JE, Brennan P, Vassiliou GS, Shlush LI (2018) Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 559:400–404
Fiancette R, Rouaud P, Vincent-Fabert C, Laffleur B, Magnone V, Cogné M, Denizot Y (2011) A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3′ regulatory region-driven c-myc transgene. J Immunol 187:5772–5782
Ryan RJ, Drier Y, Whitton H et al (2015) Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma. Cancer Discov 5:1058–1071
Zhou H, Schmidt SC, Jiang S, Willox B, Bernhardt K, Liang J, Johannsen EC, Kharchenko P, Gewurz BE, Kieff E, Zhao B (2015) Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe 17:205–216
Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA (2014) A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med 20:1130–1137
Wood CD, Veenstra H, Khasnis S, Gunnell A, Webb HM, Shannon-Lowe C, Andrews S, Osborne CS, West MJ (2016) MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs. Elife:5
Crowther-Swanepoel D, Broderick P, Di Bernardo MC et al (2010) Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 42:132–136
Ryan RJH, Petrovic J, Rausch DM et al (2017) A B cell regulome links Notch to downstream oncogenic pathways in small B cell lymphomas. Cell Rep 21:784–797
Fabbri G, Holmes AB, Viganotti M, Scuoppo C, Belver L, Herranz D, Yan XJ, Kieso Y, Rossi D, Gaidano G, Chiorazzi N, Ferrando AA, Dalla-Favera R (2017) Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 114:E2911–E2919
Sanchez-Martin M, Ferrando A (2017) The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood. 129:1124–1133
Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O’Neil J, Neuberg D, Weng AP, Aster JC, Sigaux F, Soulier J, Look AT, Young RA, Califano A, Ferrando AA (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 103:18261–18266
Belver L, Yang AY, Albero R et al (2019) GATA3-controlled nucleosome eviction drives MYC enhancer activity in T-cell development and leukemia. Cancer Discov 9:1774–1791
Yashiro-Ohtani Y, Wang H, Zang C et al (2014) Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc Natl Acad Sci U S A 111:E4946–E4953
Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA, Bernstein BE (2014) An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet 46:364–370
Choi SH, Severson E, Pear WS, Liu XS, Aster JC, Blacklow SC (2017) The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia. PLoS One 12:e0185762
Vanden Bempt M, Demeyer S, Broux M et al (2018) Cooperative enhancer activation by TLX1 and STAT5 drives development of NUP214-ABL1/TLX1-positive T cell acute lymphoblastic leukemia. Cancer Cell 34:271–285.e7
Gekas C, D’Altri T, Aligué R, González J, Espinosa L, Bigas A (2016) β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1. Leukemia. 30:2002–2010
Kamikubo Y (2018) Genetic compensation of RUNX family transcription factors in leukemia. Cancer Sci 109:2358–2363
Choi A, Illendula A, Pulikkan JA, Roderick JE, Tesell J, Yu J, Hermance N, Zhu LJ, Castilla LH, Bushweller JH, Kelliher MA (2017) RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia. Blood. 130:1722–1733
Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, Minder JL, Mercan F, Wang E, Eckersley-Maslin MA, Campbell AE, Kawaoka S, Shareef S, Zhu Z, Kendall J, Muhar M, Haslinger C, Yu M, Roeder RG, Wigler MH, Blobel GA, Zuber J, Spector DL, Young RA, Vakoc CR (2013) Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev 27:2648–2662
Chan HL, Beckedorff F, Zhang Y, Garcia-Huidobro J et al (2018) Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms. Nat Commun 9:3377
Pulikkan JA, Hegde M, Ahmad HM et al (2018) CBFβ-SMMHC inhibition triggers apoptosis by disrupting MYC chromatin dynamics in acute myeloid leukemia. Cell 174:172–186.e21
Knoechel B, Bhatt A, Pan L et al (2015) Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud 1:a000539
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown M, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 146:904–917
Donato E, Croci O, Sabò A, Muller H, Morelli MJ, Pelizzola M, Campaner S (2017) Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors. Leukemia. 31:479–490
Di Micco R, Fontanals-Cirera B, Low V et al (2014) Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep 9:234–247
Cheong JK, Zhang F, Chua PJ, Bay BH, Thorburn A, Virshup DM (2015) Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers. J Clin Invest 125:1401–1418
Minzel W, Venkatachalam A, Fink A et al (2018) Small molecules co-targeting CKIα and the transcriptional kinases CDK7/9 control AML in preclinical models. Cell 175:171–185.e25
Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J (2015) Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 525:543–547
Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR, Weirauch MT (2018) The human transcription factors. Cell. 172:650–665
Mikhaylichenko O, Bondarenko V, Harnett D, Schor IE, Males M, Viales RR, Furlong EEM (2018) The degree of enhancer or promoter activity is reflected by the levels and directionality of eRNA transcription. Genes Dev 32:42–57
Dao LTM, Galindo-Albarrán AO, Castro-Mondragon JA, Andrieu-Soler C, Medina-Rivera A, Souaid C, Charbonnier G, Griffon A, Vanhille L, Stephen T, Alomairi J, Martin D, Torres M, Fernandez N, Soler E, van Helden J, Puthier D, Spicuglia S (2017) Genome-wide characterization of mammalian promoters with distal enhancer functions. Nat Genet 49:1073–1081
Gonda TJ, Ramsay RG (2015) Directly targeting transcriptional dysregulation in cancer. Nat Rev Cancer 15:686–694
Acknowledgments
We apologize to all authors whose work has not been cited.
Authorship
L.B., A.B., and G.V. collected the data and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Benetatos, L., Benetatou, A. & Vartholomatos, G. Enhancers and MYC interplay in hematopoiesis. J Mol Med 98, 471–481 (2020). https://doi.org/10.1007/s00109-020-01891-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-020-01891-1